Claude for Life Sciences
Last reviewed
Jun 9, 2026
Sources
12 citations
Review status
Source-backed
Revision
v2 · 1,186 words
Improve this article
Add missing citations, update stale details, or suggest a clearer explanation.
Suggest edit
CtrlK
Last reviewed
Jun 9, 2026
Sources
12 citations
Review status
Source-backed
Revision
v2 · 1,186 words
Add missing citations, update stale details, or suggest a clearer explanation.
Claude for Life Sciences is an industry-specific offering from Anthropic that adapts its Claude models for scientific research and drug development, packaging connectors to laboratory and literature platforms, reusable instruction sets called Agent Skills, and support for biotech, pharmaceutical, and academic users. Announced on October 20, 2025, it was the company's second formal industry solution after Claude for Financial Services.[1][2]
Anthropic released Claude for Financial Services on July 15, 2025, its first packaged offering aimed at a single vertical, bundling its models with connectors to data providers and with expanded usage for analysts and portfolio managers.[3] Life sciences was positioned as the next target. The company had recruited Eric Kauderer-Abrams as head of biology and life sciences months before the launch, and he framed the ambition in commercial terms. "We want a meaningful percentage of all of the life science work in the world to run on Claude, in the same way that that happens today with coding," he told CNBC.[2][4]
The pitch rests on the breadth of work a research organization does between an initial idea and a regulatory filing. Anthropic described Claude for Life Sciences as covering literature review, hypothesis generation, data analysis, and the drafting and review of regulatory submissions, rather than a single narrow task.[1][2] Anthropic is a public benefit corporation, and the announcement tied the effort to that charter, stating that increasing the rate of scientific progress is part of its mission.[1]
The offering is built on Claude Sonnet 4.5, the model Anthropic released in late September 2025 and described as its most capable at the time of the launch.[1] Anthropic reported that Sonnet 4.5 scored 0.83 on Protocol QA, a benchmark that tests understanding of laboratory protocols, against a human baseline of 0.79 and the earlier Claude Sonnet 4 score of 0.74.[1][5] The company did not publish full methodology for the figure.[5]
Capabilities are grouped around stages of the research process. For discovery work, Claude can summarize and cite biomedical literature and propose testable hypotheses. For bioinformatics, it can process and analyze genomic data, including through Claude Code, and present results as slides, documents, or notebooks. Through the Benchling connector it can draft study protocols, standard operating procedures, and consent documents. For compliance work it can draft and review regulatory submissions and compile supporting data.[1][5] Anthropic and outside coverage described demonstrations, such as preclinical dosing analysis and regulatory report generation, that compressed work measured in days into minutes.[2][6]
At launch the product was available through claude.com and the AWS Marketplace, with Google Cloud Marketplace listed as forthcoming.[5] To help organizations adopt it, Anthropic named implementation partners including Deloitte, KPMG, Caylent, and Tribe AI, later listing Accenture, PwC, Quantium, Slalom, and Turing among the consulting firms working on the offering.[6][7]
The connectors let Claude read from systems scientists already use rather than from manually exported files. They are built on the Model Context Protocol (MCP), Anthropic's open standard for linking models to external tools and data. The Benchling integration returns answers with one-click traceability back to source experiments and notebooks, and preserves the customer's existing permissions and audit logs.[1][8] The following platforms were named as connectors at launch.
| Connector | Type | What it provides |
|---|---|---|
| Benchling | Lab data platform | R&D records, notebooks, protocol and document drafting with source links |
| 10x Genomics | Genomics tools | Single-cell and spatial genomics data |
| PubMed | Literature database | Biomedical research literature |
| BioRender | Scientific figures | Diagram and figure assets |
| Synapse.org | Research data commons | Collaborative and shared research datasets |
| Scholar Gateway (Wiley) | Publisher content | Access to Wiley scientific literature |
The Benchling tie-up was announced jointly. Ashu Singhal, Benchling's co-founder and president, said "AI in R&D only works through an ecosystem," and Anthropic's Kauderer-Abrams said that with Benchling's data foundation "Claude helps teams move from research questions to results faster." Access to that connector is limited to Benchling customers who have Benchling AI enabled.[8]
Agent Skills are packaged instruction sets, with any scripts and reference files, that guide Claude through a defined procedure so the same workflow can be reused across an organization. At launch Anthropic shipped one named skill for life sciences, single-cell-rna-qc, which performs quality control and filtering on single-cell RNA sequencing data following scverse best practices.[1][5] Reported use cases spanned the research lifecycle, from compiling literature reviews and generating hypotheses through genomic analysis to drafting regulatory documentation.[1][2]
Anthropic also lists existing enterprise connectors that life sciences teams can combine with the science-specific ones, including Google Workspace, Microsoft SharePoint, OneDrive, Outlook and Teams, plus the data platforms Databricks and Snowflake.[5] These sit alongside Claude for Work enterprise deployments, and Anthropic positioned the offering for roles such as researchers, clinical coordinators, and regulatory affairs managers.[1]
On January 11, 2026, Anthropic expanded the offering and introduced a companion Claude for Healthcare product with HIPAA-ready infrastructure for providers and payers. The expansion added connectors including Medidata, ClinicalTrials.gov, the bioRxiv and medRxiv preprint servers, Open Targets, the ChEMBL compound database, the Owkin pathology platform, and ToolUniverse. It also added Agent Skills for scientific problem selection, conversion of instrument data to the Allotrope format, bioinformatics bundles covering scVI-tools and Nextflow, and clinical trial protocol drafting.[9][10]
Coverage treated the launch as Anthropic's entry into a large vertical, with CNBC, SiliconANGLE, and trade outlets framing it as the company's first formal move into life sciences.[2][6] Reporting noted that several large pharmaceutical companies were already using Claude. Anthropic cited Sanofi and Novo Nordisk as customers at launch, and later coverage listed Sanofi, Novo Nordisk, and AbbVie among pharma users of Claude.[5][11]
Anthropic deepened the commitment the following spring. In early April 2026, multiple outlets reported that the company was acquiring Coefficient Bio, a small New York startup whose founders previously worked on machine learning at Genentech, in a stock deal valued at about $400 million, folding the team into its healthcare work to push further into drug discovery.[11][12] The Benchling integration drew its own attention as evidence that incumbent R&D software vendors were partnering with foundation model providers rather than building competing assistants alone.[8]